FDA adds heart warning to Pfizer anti-smoking pill

Jun 16, 2011 By MATTHEW PERRONE , AP Health Writer

(AP) -- Federal health regulators are warning doctors and patients that Pfizer's anti-smoking drug Chantix may slightly increase the risk of heart attack and other cardiovascular problems.

The said Thursday a study of 700-heart disease patients taking Chantix showed a small uptick in heart problems among those taking the drug versus those taking placebo. The agency stressed that the drug helped patients quit smoking and that this benefit "should be weighed against its potential risks when deciding to use the drug in smokers with cardiovascular disease."

Chantix is a twice-daily tablet that works by binding to nicotine receptors in the brain, reducing the symptoms of withdrawal.

The FDA will add new warnings to the drug's label about the study's findings. Patients will also receive an updated medication guide with their Chantix prescription that talks about the heart risks.

Drugmaker Pfizer will be required to analyze a large group of studies to further define the heart risk, according to the FDA. The company said in a statement that "the overall rates reported in the study were low."

Approved in May 2006, Chantix has been used by millions of patients in the U.S., though sales have declined since 2008 when the drug was first linked to psychological side effects, including depression and suicidal thoughts. It currently carries a boxed warning, the most serious type, about those risks. GlaxoSmithKline's competing drug, Zyban, carries the same warning.

New York-based . reported sales of $755 million for Chantix last year. Most of the drug's new sales have been driven by patients outside the U.S. Company shares dipped 5 cents to $20.14 in afternoon trading.

Explore further: Seniors successfully withdraw from meds

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA: New warning needed for Chantix

Feb 03, 2008

The U.S. Food and Drug Administration Friday called for increased awareness of the health risks of the smoking cessation drug varenicline.

FDA requires Chantix, Zyban to have warning

Jul 01, 2009

(AP) -- The Food and Drug Administration will require two smoking-cessation drugs, Chantix and Zyban, to carry the agency's strongest safety warning over side effects including depression and suicidal thoughts.

FDA clears Eli Lilly's blood thinner Effient

Jul 10, 2009

(AP) -- The Food and Drug Administration on Friday approved a highly anticipated blood thinner from Eli Lilly, though the drug must carry the agency's sternest warning because of its bleeding risks.

Recommended for you

Seniors successfully withdraw from meds

Sep 19, 2014

Elderly people have proved receptive to being de-prescribed medications, as part of a trial aimed at assessing the feasibility of withdrawal of medications among older people.

Flu vaccine for expectant moms a top priority

Sep 18, 2014

Only about half of all pregnant women in the U.S. get a flu shot each season, leaving thousands of moms-to-be and their babies at increased risk of serious illness.

Experts want restrictions on testosterone drug use (Update)

Sep 17, 2014

Federal health experts said Wednesday there is little evidence that testosterone-boosting drugs are effective for treating common signs of aging in men and that their use should be narrowed to exclude millions of Americans ...

User comments : 0